Sofiniclin

Sofiniclin (ABT 894), an agonist of nicotinic acetylcholine receptor (nAChR), is used as a potential non-stimulant research for attention-deficit/hyperactivity disorder (ADHD) [1][2].

Product Specifications

CAS Number

[799279-80-4]

Product Name Alternative

ABT 894

UNSPSC

12352005

Target

NAChR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ABT_894.html

Purity

99.63

Solubility

DMSO : 35.71 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

ClC1=C(Cl)C=C(N2C[C@]3([H])CN[C@]3([H])C2)C=N1

Molecular Formula

C10H11Cl2N3

Molecular Weight

244.13

References & Citations

[1]Zhang D, et al. ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Mov Disord. 2014 Apr;29 (4) :508-17.|[2]Zhang D, ET AL. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage. Mov Disord. 2015 Dec;30 (14) :1901-11.